Articles |
From the Department of Biochemistry and Pathology, Boston (Mass) University School of Medicine.
Correspondence to Peter Brecher, PhD, Department of Biochemistry and Pathology, Boston University School of Medicine, Whitaker Cardiovascular Institute, 80 East Concord St, Boston, MA 02118. E-mail pbrecher@acs.bu.edu.
| Abstract |
|---|
|
|
|---|
(TNF) separately did not stimulate nitrite
production, whereas IFN combined with IL-1 or TNF
synergistically induced iNOS, both at the level of steady state mRNA
and nitrite accumulation. Steady state mRNA levels for iNOS were
obvious as early as 3 hours after the addition of IFN+TNF and remained
elevated for at least 72 hours. Sodium salicylate inhibited
cytokine-induced nitrite accumulation in a time- and
dose-dependent manner (IC50, 750 µmol/L). The
inhibition was reversible and occurred when salicylate was added either
before or after cytokine induction. Aspirin (1 mmol/L) also
inhibited nitrite production, whereas
indomethacin (25 µmol/L) or acetaminophen
(100 µmol/L) did not. TNF, either alone or combined with IFN,
significantly stimulated prostaglandin
E2, which was inhibited by either salicylate (4
mmol/L) or indomethacin (25 µmol/L). Salicylate, when
given either before or after IFN+TNF, reduced mRNA levels of iNOS
induced by cytokines. Salicylate did not affect iNOS enzymatic
activity when added to the cytosolic lysate, although it was able to
reduce enzymatic activity to 32% of induced levels when given to
intact cells. These studies implicate cardiac fibroblasts as a source
of NO in inflammatory cardiac diseases and suggest a possible
therapeutic role for salicylate and aspirin in diminishing the steady
state levels of iNOS mRNA.
Key Words: nitric oxide fibrosis prostaglandins cell culture
| Introduction |
|---|
|
|
|---|
In vivo, the induction of iNOS has been proposed to play a role in a variety of inflammatory cardiovascular diseases, including cardiac allograft rejection,9 septic shock,10 and myocarditis.5 Although the role of NO in each disease process has not been completely established, NO has been associated in vivo with reduced cardiac contractility via cGMP elevation,5 vascular hypotension, and antimicrobial activity against various parasites.11 Therapeutic agents such as the glucocorticoids have the ability to inhibit iNOS if given before but not after the induction of this enzyme by cytokines12 ; however, glucocorticoids do not improve survival in patients with septic shock,13 perhaps because of their administration after the induction of iNOS.
The salicylates are commonly used anti-inflammatory agents. Their
mechanism of action is still unresolved. It has been postulated that
their efficacy lies in the inhibition of
cyclooxygenase. Yet much higher doses of aspirin
are needed to treat chronic inflammatory diseases14 than
are required to inhibit prostaglandin synthesis. In
addition, aspirin inhibits cyclooxygenase by
acetylation, yet salicylate lacks an acetyl group and is
ineffective as a cyclooxygenase
inhibitor. Nonetheless, salicylate is used to treat
inflammation at doses similar to those used for aspirin. Salicylate is
known to have additional effects. For example, in HeLa cells,
salicylate activates human heat shock transcription
factor15 ; in Drosophila salivary glands, it
induces heat shockresponsive chromosomal puffs and heat shock
transcription factor binding16 ; and in plants, it
activates pathogenesis-related genes in response to
infection and injury.17 18 Recently, salicylate or aspirin
has been shown to inhibit the activation of the transcription factor
NF-
B in human monocytes via a
cyclooxygenase-independent
mechanism.19
In the present study, we have sought to determine whether cultured
cardiac fibroblasts are a source of NO when stimulated by
cytokines. Additionally, we have examined whether sodium
salicylate and other NSAIDs can, at pharmacological doses, diminish the
induction of iNOS by cytokines. Having found that salicylates
do inhibit iNOS in cardiac fibroblasts, we have characterized this
effect and may have implicated the transcription factor NF-
B as part
of the inhibitory mechanism by salicylate.
| Materials and Methods |
|---|
|
|
|---|
-32P]dCTP (10 mCi/mL) was purchased from DuPont NEN
Research Products. L-[2,3,4,5-3H]Arginine
HCl (68 Ci/mmol) was purchased from Amersham Corp. Sodium salicylate,
4-acetamido-phenol (acetaminophen),
indomethacin, LPS (Escherichia coli
0127:B8), acetylsalicylic acid, fatty
acidfree BSA, insulin/transferrin/selenium mixture,
dexamethasone, and all other reagents were purchased from
Sigma Chemical Co. All reagents were of the highest purity available
unless noted otherwise.
Cell Culture
Primary cultures of neonatal rat cardiac fibroblasts were
prepared using the following modifications of previously published
methods.20 21 Hearts were removed under aseptic conditions
from four 8-day-old Sprague-Dawley rats (Harlan Sprague
Dawley, Indianapolis, Ind) that were overdosed by sodium
pentobarbital (Abbott Laboratories). All procedures followed were in
accordance with institutional guidelines. The ventricles were minced
into 2- to 3-mm3 fragments. Digestion was performed by four
to six 15-minute periods of incubation at 37°C with HEPES-buffered
saline solution containing (mmol/L) HEPES-NaOH 20, pH 7.6, NaCl 130,
KCl 3, NaH2PO4 1, and glucose 4, along with 3.3
µmol/L phenol red containing 0.1% collagenase IV
(Sigma), 0.1% trypsin (GIBCO), 15 µg/mL DNase I (Sigma), and 1.0%
chicken serum (GIBCO) at 37°C. At the end of each cycle, the
supernatant was stored on ice after the addition of newborn calf serum
(10% [vol/vol]) to neutralize trypsin. The dissociated cells were
collected by centrifugation at 1000g for 10
minutes at 4°C and resuspended in DMEM/F-12 Ham supplemented with 5%
horse serum, 3 mmol/L pyruvic acid, 100 µmol/L ascorbic acid, 5
µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL sodium selenite, 100
U/mL penicillin, 100 µg/mL streptomycin, and 0.25 mg/L amphotericin
B. To selectively enrich for fibroblasts, a differential attachment
procedure was used. The cells were plated into one 75-cm2
tissue culture flask (Falcon) and incubated at 37°C in a humidified
atmosphere (5% CO2/95% air) for a 3- to 4-hour
period. During this time, the majority of myocardiocytes
remained in suspension, whereas the nonmyocardiocytes
attached more readily to the flask. Subsequently, the medium containing
the myocardiocytes was aspirated and discarded.
Highly enriched cultures of fibroblasts were prepared by serial passage
of cells obtained from the initial differential attachment
procedure.22 The cells were cultured to near confluence
(48 to 72 hours) before harvesting with a 0.05% trypsin/0.02% EDTA
solution (GIBCO). The cultures were passaged twice and replated each
time at 1:3 in DMEM/F-12 Ham supplemented with 10% FCS. For the final
passage, cells were cultured to confluence in 50-cm2
culture dishes, which were washed once with phosphate-buffered
saline before switching to DMEM/F-12 Ham supplemented with 0.5% fatty
acidfree BSA for 24 hours. Using this procedure, highly enriched
fibroblast cultures (>98%) were obtained as measured by light
microscopy and immunohistochemical staining for smooth muscle cell
-actin (DAKO Corp). To determine which cells were iNOS
immunoreactive, 24-hour serum-starved cells were treated with
IFN+IL-1 for 24 hours. These were stained with a polyclonal rabbit
anti-mouse iNOS primary antibody (Affinity Bioreagents) and
developed with a Vectastain ABC-AP kit (Vector). It was determined that
almost all cells were strongly immunoreactive for iNOS (data not
shown). Thus, a small percentage of cells were not making all the
nitrite. Cells in the third to fourth passages were used for all
experiments and were maintained in the absence of serum for 24 to 48
hours before use.
Stock solutions of the various growth factors were used as recommended by the manufacturer. All agents were diluted directly into the culture medium. Control cultures treated with the diluent gave results that were indistinguishable from untreated control cultures.
RNA Isolation, Gel Electrophoresis, and
Analysis
Total cellular RNA was isolated from fibroblasts by the acid
guanidinium thiocyanatephenolchloroform
method.23 Typically, two confluent Petri dishes of
100-cm2 surface area yielded 50 to 80 µg of total RNA.
RNA was quantified by absorbance at 260 nm. Northern blot
analysis was carried out essentially as previously
described.24 Total RNA (either 15 or 10 µg per lane) was
separated by 2.5 mol/L formaldehyde/0.9% agarose gel electrophoresis
and transferred to a nylon membrane (Nytran, Schleier & Schuell). The
cDNA probes for rat iNOS, human GAPDH, and ß-actin were labeled
with [
-32P]dCTP by a random prime labeling method
(Amersham). After ultraviolet light cross-linking, RNA
immobilized on the membrane was hybridized with the labeled
probes at 65°C for 16 hours. The membrane was washed in serial
dilutions starting at 1x SSC/0.5% SDS and ending at 0.25x SSC/0.13%
SDS at 65°C. Each wash lasted 20 minutes.
Autoradiography was performed with intensifying
screens at -80°C.
Determination of Nitrite
Cells were grown to near confluence in 24-well plates (Corning).
The medium was changed to DMEM/F-12 Ham lacking phenol red for 24 hours
before the addition of cytokines or other experimental agents.
After the designated time, the conditioned medium was assayed for
nitrite by the Griess reagent.25 Fifty microliters of
conditioned medium was mixed with an equal volume of 1%
sulfanilamide/5% H3PO4 in a 96-well plate
(Costar) and allowed to equilibrate for 5 minutes. Subsequently, 50
µL of 0.1% N-1-napthylethylene-diamine
dihydrochloride, which reacts to form a purple azo dye, was added. The
absorbance at 570 nm was read by a microplate reader (Dynatech MR 600)
and calibrated to nitrite standards. The lower limits of sensitivity
for nitrite in this assay was 2 µmol/L. All nitrite values were
calculated using absorbance readings within the linear range of the
assay. Sodium salicylate, or other drugs used, did not interfere with
the nitrite assay at the relevant concentrations. Within an experiment,
cells were routinely checked for differences in total protein
concentration between wells. No significant differences were found, as
determined by ANOVA. Cell density did not affect the experimental
results, although it influenced the overall amount of nitrite that
accumulated. Experiments were repeated with at least two different
preparations of primary cells obtained from different sets of animals,
and results were comparable in all cases.
For each experiment, values for a given treatment group were obtained using triplicate wells, each containing cells from the appropriate passage. Each well was used to obtain a nitrite value. All experiments reported in this study were repeated at least once using a separate set of cells obtained from a different primary source. Statistical comparisons were made from different experiments, and there was never any major difference in the changes observed when comparisons were made between cells obtained from different primary cultures.
Preparation of cDNA Probes
Rat iNOS cDNA plasmid for Northern blot analysis was
prepared by polymerase chain reaction as previously
reported.26 An insert of Kpn
IBamHI restriction fragment of the rat iNOS plasmid
(kindly provided by Dr Robert A. Star, University of Texas Southwestern
Medical Center) was used as the cDNA probe for Northern blot
analysis. The probe was sequenced and found to correspond
exactly to a region of macrophage iNOS. The cDNA probe for
human GAPDH was purchased from the American Type Culture Collection.
The cDNA probe for rat ß-actin was obtained from Dr S. Farmer,
Boston University School of Medicine.27
PGE2 Measurements
Prostaglandins were measured according to the
directions supplied by Cayman Chemicals in their polyclonal enzyme
immunoassay kit. Briefly, confluent cells were grown as for nitrite
determinations in 0.5 mL of medium in 24-well plates. Cells were made
quiescent for 48 hours in 0.5% fatty acidfree BSA-supplemented
DMEM/F-12 Ham lacking phenol red. Drugs were added 30 minutes before
cytokines. All cytokines were added directly to the
medium. Six hours later, the medium was removed and
centrifuged. The supernatant (50 µL) was assayed for
immunodetectable PGE2 using an enzyme immunoassay with
rabbit antiserum specific for PGE2. All assays were done in
duplicate and at two different dilutions. The lower limit of
sensitivity for this assay is 115 pg/mL, and all values reported were
within the linear range of the assay.
Selection of Time Points for Assays
Nitrite assays were performed on samples from cells treated for
12 to 96 hours with cytokines. Northern blots were performed on
total RNA extracted from cells 1 to 72 hours after the addition of
cytokines. PGE2 measurements were made on samples
taken 6 hours after IFN+TNF treatment. Since induction of iNOS mRNA
precedes nitrite accumulation, we have routinely obtained total RNA 24
hours after treatment and performed nitrite measurements 48 hours after
treatment. The earliest detectable changes in mRNA appeared between 3
to 6 hours after cytokine stimulation, whereas detectable
nitrite was obvious after 12 to 24 hours. PGE2
production was rapid, occurring within minutes and persisting
for at least 6 hours. NOS enzymatic activity was assayed after 24 hours
of cytokine treatment.
NOS Assay
NOS activity was determined by measuring the formation of
[3H]L-citrulline from
[3H]L-arginine.28 Confluent
cardiac fibroblasts were trypsinized from 10-cm Petri dishes. Cells
frozen at -80°C were thawed rapidly and homogenized
for 1 minute in a glass/glass homogenizer. The
homogenization buffer contained 0.32 mol/L sucrose,
20 mmol/L HEPES, pH 7.2, 0.5 mmol/L EDTA, and 3 mmol/L dithiothreitol.
The homogenate was centrifuged for 30 minutes at
4°C and 10 000g. Enzymatic reactions were conducted at
37°C for 1 hour in buffer containing 20 mmol/L HEPES, pH 7.2, 50
µmol/L L-arginine (
370 000 cpm of
L-[2,3,4,5-3H]arginine HCl, 68 Ci/mmol), 2
mmol/L NADPH, 1 mmol/L CaCl2, 30 U/mL
calmodulin, 10 µmol/L tetrahydrobiopterin, 10 µmol/L
FAD, 3 mmol/L dithiothreitol, 1 mmol/L phenylmethylsulfonyl
fluoride, 1 µmol/L pepstatin A, 2 µmol/L leupeptin,
100
µg of crude cytosolic protein, and other test agents as indicated, in
a final incubation volume of 200 µL. NOS specific activity was
determined by running a blank without NADPH. For samples that tested
the effect of salicylate on NOS enzymatic activity, salicylate was
added to the final reaction volume at a final concentration of 4
mmol/L. Enzymatic reactions were initiated at 37°C by addition of
enzyme-containing supernatant. Enzymatic reactions were terminated
by the addition of 1.2 mL of ice-cold stop buffer, and samples were
chromatographed as described below. Stop buffer consisted of
(mmol/L) sodium acetate 20, HEPES 5, pH 5.5, L-citrulline
1, EDTA 2, and EGTA 2.
Samples (1.4 mL) prepared as described above were applied to columns (1-cm diameter) containing 1 mL of Dowex AG50W-X8 (Na+ form prepared from the H+ form) that had been preequilibrated with stop buffer. The eluate was collected in a liquid scintillation vial. Columns were eluted with 2 mL of stop buffer and collected in the same vial. Ecoscint (16 mL, ICN) was added to each vial, and samples were counted in an LKB 1214 Rackbeta liquid scintillation counter (Wallac). Enzyme activity is expressed as picomoles citrulline formed per minute per milligram of protein in the crude cell cytosolic extract. Duplicate samples were incubated both with and without NADPH, and the increased value of disintegrations per minute with NADPH was determined as NOS specific activity.
Protein Determination
Protein concentration of cell lysates was measured by the
Bradford procedure using the protein dye reagent from BioRad
Laboratories and BSA as a standard.
Statistical Analysis
Data are expressed as mean±SEM. Statistical analysis
was performed by ANOVA, followed by a two-tailed Student's
t test. A value of P<.01 was considered
statistically significant. Analysis was performed on the data
shown in each figure, which was representative of two
additional experiments.
| Results |
|---|
|
|
|---|
30 µmol/L after 48 hours of incubation with a single
addition of the two cytokines, and the order of addition did
not influence the results. In separate experiments, shown in Fig 1B
|
Northern blot analysis (Fig 1C
) shows that the combination
treatment of IFN (400 U/mL) and IL-1 (5 ng/mL) stimulated the steady
state accumulation of mRNA for iNOS 24 hours after cytokine
treatment. The transcript for iNOS was not detectable in untreated
cells. IL-1 and IFN added alone also failed to induce the 4.4-kb
transcript for iNOS. GAPDH levels were unchanged by IFN and IL-1
treatment, added alone or in combination.
The combination of IFN and IL-1 increased nitrite production in
a time-dependent manner (Fig 2A
), reaching a maximum
after 48 hours. When TNF (1700 U/mL)+IFN was added as a combination to
cells, a progressive increase in nitrite accumulation was found, which
did not plateau after 48 hours but increased continuously for 96 hours.
The order of addition of the cytokines did not affect the
results. When added alone, neither TNF, IFN, nor IL-1 resulted in
any nitrite accumulation throughout the time frame of the
experiment.
|
The combination of IFN (480 U/mL)+TNF (850 U/mL) also stimulated the
steady state accumulation of iNOS mRNA (Fig 2B
). Northern blot
analysis with the rat iNOS cDNA probe revealed one major band
corresponding to the reported 4.4-kb size of mouse iNOS29
and two minor bands of
7 and 9 kb. These additional transcripts have
been documented in many studies of cytokine stimulation
followed by hybridization for iNOS mRNA. They do not follow
cell-specific or cytokine-specific
patterns,12 30 31 32 and the significance of these additional
bands is unknown. Untreated cells or cells treated for only 1 hour with
both cytokines had no detectable iNOS mRNA, whereas by 6 hours,
the transcript was clearly visible. Steady state mRNA levels were high
at 24 hours and remained elevated for at least 72 hours. We
consistently observed an approximately twofold increase in
GAPDH mRNA after 24 hours of treatment with IFN+TNF.
Salicylate Inhibits iNOS Both Before and After
Cytokine Addition
Sodium salicylate (4 mmol/L) almost completely inhibited the
IFN+TNF-induced nitrite production (Fig 3A
). Sodium salicylate was effective whether given 30
minutes before or 30 minutes after the addition of the
cytokines to the incubation medium. A relatively high dose of
salicylate was needed (IC50, 750 µmol/L), with
only a small reduction in nitrite accumulation as the dose of
salicylate was varied from 0.1 to 100 µmol/L. Untreated cells and
cells treated only with sodium salicylate produced no nitrite.
Different preparations of cardiac fibroblasts from separate primary
cultures all showed an inhibition of cytokine-induced
nitrite accumulation by sodium salicylate, with a dose-response
pattern almost identical to that shown in Fig 3A
. Fig 3B
shows a
dose-response curve with and without 4 mmol/L salicylate. Nitrite
accumulation was the measured response, and the dose of TNF was varied
(IFN was held constant at 480 U/mL). EC50 of
600 U/mL
for TNF was obtained, which reached a maximum at TNF concentrations
>850 U/mL. In the presence of sodium salicylate, nitrite
concentrations were significantly reduced at every dose tested, and the
rightward shift of the dose-response curve suggested that
salicylate was acting as an antagonist. A double reciprocal
plot in the Lineweaver-Burk format revealed similar dissociation
constants but different maximal effects for the agonist (IFN+TNF) and
salicylate dose responses (data not shown), consistent with a
noncompetitive interaction.33
|
To further characterize the inhibition of nitrite accumulation by
salicylate, cells were stimulated with IFN (480 U/mL)+TNF (850 U/mL),
and sodium salicylate (4 mmol/L) was added at different times, either
before or after cytokine treatment (Fig 4
).
Sodium salicylate was an equally effective inhibitor of
nitrite accumulation if given either 1 hour before or 3 hours after the
addition of cytokines. The ability of salicylate to inhibit
nitrite accumulation diminished progressively when given 6, 17, or 26
hours after the addition of cytokines, although the inhibition
was still observed even at the latest time interval tested.
|
To determine if the inhibition of nitrite production by
salicylate was due to a decrease in steady state mRNA levels of iNOS,
Northern blot analysis (Fig 5
) was performed on
quiescent cardiac fibroblasts treated in the presence or absence of
cytokines and salicylate. Control cells received no drugs.
Salicylate (4 mmol/L) alone was given to cells for 24 hours.
Cytokine-treated cells received either IFN+TNF for 24 hours
or IFN+TNF for 24 hours, with salicylate (4 mmol/L) being given after
the cytokines were present for 6 hours. Total RNA was
extracted from cells, and Northern blot analysis was performed.
In control and salicylate-treated samples, no iNOS mRNA was
evident. There was a clear induction in IFN+TNFtreated cells, which
was dramatically reduced by the addition of salicylate 6 hours after
the start of cytokines. The ß-actin transcript
shows the even loading of the lanes with RNA. The GAPDH message
consistently increases after 24 hours of IFN+TNF treatment.
|
Effects of Sodium Salicylate Are Reversible
When cells were treated with 4 mmol/L salicylate for either 24 or
48 hours and then washed and subsequently incubated for an additional
24 hours with cytokines, nitrite production was
comparable to that found when cytokines were added to untreated
cells (data not shown), indicating that the effects of salicylate were
reversible. Furthermore, 4 mmol/L salicylate treatment did not cause
cell detachment or an increase in trypan blue staining and did not
affect cell growth within a 48-hour period. However, when cells were
treated for 48 hours with 20 mmol/L salicylate, appreciable cell
detachment was observed. Several other groups have used salicylate in
cell culture at doses up to 20 mmol/L with no harmful effects.
Salicylate (20 mmol/L) has been shown not to affect RNA
polymerase II activity in cultured HeLa cells.15
Aspirin or Salicylate Inhibits iNOS Independently of
Cyclooxygenase
The inhibitory effect of sodium salicylate on nitrite
production was compared with other NSAIDs as well as with
acetaminophen. Each drug was given 30 minutes before
combined cytokine treatment with IFN+TNF. Aspirin (2.5 mmol/L;
IC50, 750 µmol/L) inhibited nitrite accumulation
and was more potent than sodium salicylate in reducing nitrite after 48
hours. In contrast, indomethacin (25 µmol/L) and
acetaminophen (100 µmol/L) were ineffective. Since
indomethacin is known to inhibit
prostaglandin production, the effects of the
various NSAIDs on PGE2 production by the cardiac
fibroblasts were also assessed (Fig 6B
).
PGE2 was determined in quiescent cells that were stimulated
for 6 hours by cytokines in the absence or presence of the
different drugs. Untreated cells or cells treated with either
indomethacin, ethanol vehicle, or IFN produced a basal
level of
4 ng/mL of PGE2. In contrast, TNF alone or
IFN+TNF resulted in a greater than twofold increase in
PGE2. High-dose sodium salicylate (4 mmol/L) and
indomethacin (25 µmol/L) pretreatment effectively
prevented the cytokine-induced stimulation of
PGE2.
|
Salicylate Inhibits iNOS mRNA Accumulation in a
Time-Dependent Manner
To determine if the inhibition of nitrite production by
salicylate was at the mRNA level, Northern blot analysis (Fig 7
) was performed on quiescent cardiac fibroblasts
treated in the presence or absence of cytokines and salicylate.
(Salicylate was administered to the cells 30 minutes before
cytokines.) IFN+TNF was added with or without sodium
salicylate, and at time 0 (control [no cytokines]), 1 hour,
or 3, 6, or 21 hours, total RNA was extracted from cells, and Northern
blot analysis was performed. At 6 and 21 hours, the striking
increase in iNOS mRNA was almost completely suppressed by salicylate
pretreatment. At 3 hours, salicylate did not appear to affect the
slight cytokine-induced increase in iNOS mRNA. iNOS
mRNA was not detectable in control cells. Once again, the GAPDH
transcript was slightly increased after 21 hours of treatment with
IFN+TNF and was effectively reduced by salicylate pretreatment (lanes
were evenly loaded, as revealed by ethidium bromide staining; data not
shown).
|
Salicylate Does Not Directly Affect iNOS Enzymatic
Activity
NOS enzymatic activity was measured (Table
) to
determine if salicylate affected iNOS activity. Quiescent cardiac
fibroblasts were either untreated (control), treated with IFN (480
U/mL)+TNF (850 U/mL) or IFN+TNF+salicylate (4 mmol/L) for 24 hours. A
cytosolic preparation was made of cells, and NOS enzymatic activity was
measured, monitoring the conversion of L-arginine to
L-citrulline. Twenty-four hours of cytokine
stimulation increased enzymatic activity from 6 to 186
pmol·min-1·mg-1.
Salicylate (4 mmol/L), when added to the cell culture medium 30 minutes
before cytokines, reduced NOS enzymatic activity to 59
pmol·min-1 ·mg-1,
which is in good agreement with nitrite and iNOS mRNA results.
Salicylate (4 mmol/L), when added to the crude cytosolic extract from
cells treated with IFN+TNF, gave results identical to those found for
extracts assayed without salicylate. This demonstrates that
salicylate's inhibitory effect is exclusively on steady
state iNOS mRNA levels and not on iNOS enzymatic activity.
|
| Discussion |
|---|
|
|
|---|
Previously, TGF-ß1 has been characterized as an inhibitor of iNOS.12 39 It has been demonstrated that the inhibition exists at the transcriptional and posttranscriptional level. In vitro, TGF-ß1 has been demonstrated to inhibit iNOS in vascular smooth muscle cells both before and after cytokine induction by IL-1 or TNF. In the present study, TGF-ß1 could inhibit nitrite accumulation only if present before cells were induced but not 30 minutes after its induction by cytokines. This may point to a cell-specific or culture conditionspecific regulation of iNOS by TGF-ß1.
We tested salicylate, aspirin, and other NSAIDs to determine if they could inhibit iNOS, an enzyme upregulated in many inflammatory diseases of the heart, including cardiac transplant rejection,9 septic shock,10 endocarditis, and myocarditis. Sodium salicylate in a time-dependent manner inhibited nitrite accumulation stimulated by IFN+TNF. Interestingly, salicylate inhibited iNOS whether given before or after the induction by cytokines. This may have important implications for the treatment of diseases such as septic shock, which present clinically with the enzyme already induced.13 Salicylate, when present 30 minutes or 3, 6, 17, or 26 hours after cytokine treatment, was able to significantly reduce nitrite levels at the end of the 48-hour experiment. Additionally, salicylate had the ability to reduce iNOS mRNA when given after induction by IFN+TNF. At the mRNA level, inhibition by salicylate was evident at 6 and 21 hours after cytokine induction but not at 3 hours. Thus, salicylate may be inhibiting a secondary effect of cytokines that requires at least 3 hours to develop40 and that could itself activate iNOS.1 Oxidative stress is a possible phenomenon that meets these criteria.
To test the specificity of salicylate in the inhibition of iNOS, the efficacy of other NSAIDs was tested in culture at concentrations equivalent to maximal therapeutic levels reported in human plasma.13 14 Of the three agents (aspirin, indomethacin, and acetaminophen), only aspirin could inhibit nitrite accumulation. Aspirin was more potent than salicylate and inhibited iNOS in a dose-dependent manner. Acetaminophen (100 µmol/L) could not inhibit nitrite accumulation. Indomethacin (25 µmol/L), a very potent cyclooxygenase inhibitor, had no ability to reduce nitrite accumulation, although it effectively inhibited PGE2. Other studies have demonstrated that indomethacin cannot inhibit iNOS41 and may actually increase nitrite production in certain instances.42 Thus, cyclooxygenase inhibition is not sufficient for iNOS inhibition.
The inducibility of iNOS by cytokines has been formally shown
to be dependent on two transcription factors: IFN regulatory factor-1
(for IFN inducibility)43 and NF-
B (for LPS
inducibility).44 The requirement in cardiac fibroblasts
for two cytokines may be a consequence of the coordinate
effects of these two transcription factors in stimulating iNOS
transcription by RNA polymerase II. Because of its
two-cytokine dependence, this system may be useful for
studying the signal transduction pathways of cytokines.
The recent demonstration that salicylate-like drugs, but not
indomethacin or acetaminophen, inhibit the
activation of NF-
B by LPS19 may implicate NF-
B in
the responses seen in our system. It has been demonstrated that LPS
inducibility of iNOS depends on the unique NF-
B sequence containing
nucleotides -85 to -76 of the murine iNOS
promoter and the binding to this region of a
cycloheximide-sensitive complex containing both p50/c-rel and
p50/RelA heterodimers of NF-
B, in partnership with additional
unidentified nuclear protein(s).44 Additionally, two
NF-
B consensus sequences have been demonstrated in the murine iNOS
promoter.45 46 The cytokines IL-1 and TNF
have signal transduction pathways that culminate in the activation of
NF-
B.47 Taken together, these studies suggest that
sodium salicylate and aspirin may be inhibiting iNOS induction via
NF-
Bdependent mechanisms. If indeed the transcription factor
NF-
B is being inhibited, then the reduction in nitrite accumulation
could be due to a transcriptional inhibition. To test this, we
confirmed that the inhibition of nitrite accumulation is correlated
with a reduction of iNOS steady state mRNA. Northern blot
analysis showed that by 6 hours and continuing for at least 21
hours, sodium salicylate inhibited the progressive increase of iNOS
mRNA in IFN+TNFstimulated cardiac fibroblasts. The inhibition of
steady state mRNA levels does not directly indicate a transcriptional
effect and could represent either decreased mRNA
production and/or increased degradation.
In summary, we have shown in the present study that inflammatory
cytokines can stimulate iNOS in cardiac fibroblasts.
Furthermore, the induction occurs only synergistically and depends on
the presence of two cytokines. We have linked two commonly used
drugs, sodium salicylate and aspirin, to the inhibition of the
accumulation of the steady state mRNA for iNOS, an enzyme known to be
upregulated during inflammation. These effects appear to be independent
of cyclooxygenase inhibition and may be dependent
on the level of oxidative stress or activation of NF-
B. The ability
of the anti-inflammatory salicylate-like drugs to curtail NOS
may provide a rationale for therapeutic options, especially in light of
the ability of these drugs to inhibit NOS after its induction.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received May 25, 1995; accepted January 5, 1996.
| References |
|---|
|
|
|---|
2. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 1992;6:3051-3064. [Abstract]
3.
Cho H, Xie Q, Calycay J, Mumford R, Swiderek K, Lee T,
Nathan C. Calmodulin is a subunit of nitric oxide
synthase from macrophages. J Exp
Med. 1992;176:599-604.
4. Brady A, Poole-Wilson P, Harding S, Warren J. Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol. 1992;263(Heart Circ Physiol 32):H1963-H1966.
5. Schulz R, Nava E, Moncada S. Induction and potential biological relevance of a Ca2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol. 1992;105:575-580. [Medline] [Order article via Infotrieve]
6.
Balligand J, Ungureanu-Longrois D, Simmons W, Pimental
D, Malinski T, Kapturczak M, Taha Z, Lowenstein C, Davidoff A, Kelly R,
et al. Cytokine-inducible nitric oxide synthase (iNOS)
expression in cardiac myocytes. J Biol Chem. 1994;269:27580-27588.
7.
Roberts A, Vodovotz Y, Roche N, Sporn M, Nathan
C. Role of nitric oxide in antagonistic effects of
transforming growth factor-ß and interleukin-1ß on the beating rate
of cultured cardiac myocytes. Mol Endocrinol. 1992;6:1921-1930.
8.
Stamler J, Singel D, Loscalzo J. Biochemistry
of nitric oxide and its redox-activated forms.
Science. 1992;258:1898-1902.
9. Yang X, Chowdury N, Cai B, Brett J, Marboe C, Sciacca R, Michler R, Cannon P. Induction of myocardial nitric oxide synthase by cardiac allograft rejection. J Clin Invest. 1994;94:714-721.
10.
Moncada S, Higgs A. The L-arginine-nitric
oxide pathway. N Engl J Med. 1993;329:2002-2012.
11. Liew FY, Millott S, Parkinson C, Palmer RMJ, Moncada S. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol. 1990;144:4794-4797. [Abstract]
12.
Perella M, Yoshizumi M, Fen Z, Tsai J, Jsieh C,
Kourembanas S, Lee M. Transforming growth factor-ß1, but not
dexamethasone, down-regulates nitric-oxide synthase
mRNA after its induction by interleukin-1ß in rat smooth muscle
cells. J Biol Chem. 1994;269:14595-14600.
13. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisone in the treatment of severe sepsis and shock. N Engl J Med. 1987;317:653-658. [Abstract]
14. Insel P. Analgesic-antipyretics and antiinflammatory agents: drugs employed in the treatment of rheumatoid arthritis and gout. In: Gilman AG, Rall T, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. 8th ed. New York, NY: McGraw Hill Publishing Co; 1990:638-681.
15.
Jurivich D, Sistonen L, Kroes R, Morimoto R.
Effect of sodium salicylate on the human heat shock response.
Science. 1992;255:1243-1245.
16. Zimarino V, Wu C. Induction of sequence specific binding of Drosophila heat shock activator protein without protein synthesis. Nature. 1987;327:727-730. [Medline] [Order article via Infotrieve]
17.
Malamy J, Carr JP, Klessig DF, Raskin I.
Salicylic acid: a likely endogenous signal in the
resistance response of tobacco to viral infection.
Science. 1990;250:1002-1004.
18.
Métraux J, Signer H, Ryals J, Ward E, Wyss-Benz
M, Gaudin J, Raschdorf K, Schmid E, Blum W, Inverardi B.
Increase in salicylic acid at the onset of systemic acquired resistance
in cucumber. Science. 1990;250:1004-1006.
19.
Kopp E, Ghosh S. Inhibition of NF-
B by sodium
salicylate and aspirin. Science. 1994;265:956-959.
20.
Orlowski J, Lingrel J. Thyroid and
glucocorticoid hormones regulate the expression of multiple
Na,K-ATPase genes in cultured neonatal rat cardiac myocytes.
J Biol Chem. 1990;265:3462-3470.
21.
Sadoshima J, Jahn L, Takahashi T, Kulik T, Izumo
S. Molecular characterization of the stretch-induced
adaptation of cultured cardiac cells. J Biol
Chem. 1992;267:10551-10560.
22.
Simpson P, Savion S. Differentiation of rat
myocytes in single cell cultures with and without proliferating
nonmyocardial cells. Circ Res. 1982;50:101-116.
23. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159. [Medline] [Order article via Infotrieve]
24.
Takasaki I, Chobanian AV, Mamuya WS, Brecher P.
Hypertension induces alternatively spliced forms of fibronectin in rat
aorta. Hypertension. 1992;20:20-25.
25. Green L, Wagner D, Glogowski J, Skipper P, Wishnok J, Tannenbaum S. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem. 1982;126:131-138. [Medline] [Order article via Infotrieve]
26. Ujiie K, Yuen J, Hogarth L, Danziger R, Star RA. Localization and regulation of endothelial nitric oxide synthase mRNA expression in the rat kidney. Am J Physiol. 1994;267:296-302.
27.
Bond J, Farmer S. Regulation of tubulin and
actin mRNA production in the rat brain: expression of a new
ß-tubulin mRNA with development. Mol Cell
Biol. 1983;3:1333-1342.
28.
Bredt DS, Snyder SH. Isolation of nitric oxide
synthetase, a calmodulin-requiring
enzyme. Proc Natl Acad Sci U S A. 1990;87:682-685.
29.
Xie Q, Cho H, Calaycay J, Mumford R, Swiderek K, Lee T,
Ding A, Troso T, Nathan C. Cloning and characterization of
inducible nitric oxide synthase from mouse macrophages.
Science. 1992;256:225-228.
30.
Koide M, Kawahara Y, Nakayama I, Tsuda T, Yokoyama
M. Cyclic AMP-elevating agents induce an inducible type of
nitric oxide synthase in cultured vascular smooth muscle cells.
J Biol Chem. 1993;268:24959-24966.
31.
Geller D, Nussler A, Di Silvio M, Lowenstein C, Shapiro
R, Wang S, Simmons R, Billiar T. Cytokines, endotoxin,
and glucocorticoids regulate the expression of inducible nitric oxide
synthase in hepatocytes. Proc Natl Acad Sci
U S A. 1993;90:522-526.
32.
Melillo G, Cox G, Biragyn A, Sheffler L, Varesio
L. Regulation of nitric-oxide synthase mRNA expression by
interferon-
and picolinic acid. J Biol
Chem. 1994;269:8128-8133.
33. Ross E. Mechanisms of drug action and the relationship between drug concentration and effect. In: Gilman AG, Rall T, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. 8th ed. New York, NY: McGraw Hill Publishing Co; 1990:33-48.
34.
Werner-Felmayer G, Werner E, Fuchs D, Hausen A,
Reibnegger G, Wachter H. Tetrahydrobiopterin-dependent
formation of nitrite and nitrate in murine fibroblasts.
J Exp Med. 1990;172:1599-1607.
35.
Jorens P, Van Overveld F, Vermeire P, Bult H, Herman
A. Synergism between interleukin-1ß and interferon-
, an
inducer of nitric oxide synthase, in rat lung fibroblasts.
Eur J Pharmacol. 1992;224:7-12. [Medline]
[Order article via Infotrieve]
36.
Lorsbach R, Murphy W, Lowenstein C, Snyder S, Russell
S. Expression of the nitric oxide synthase gene in mouse
macrophages activated for tumor cell killing.
J Biol Chem. 1993;268:1908-1913.
37. Anversa P, Olivetti G, Melissari M, Loud AV. Stereological measurement of cellular and subcellular hypertrophy and hyperplasia in the papillary muscle of adult rat. J Mol Cell Cardiol. 1980;12:781-795. [Medline] [Order article via Infotrieve]
38. Hinglais N, Heudes D, Nicoletti A, Mandet C, Laurent M, Bariéty J, Michel J-B. Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab Invest. 1994;70:286-294. [Medline] [Order article via Infotrieve]
39. Schini V, Durante W, Elizondo E, Scott-Burden T, Junquero D, Schafer A, Vanhoutte P. The induction of nitric oxide synthase activity is inhibited by TGF-ß1, PDGFAB and PDGFBB in vascular smooth muscle cells. Eur J Pharmacol. 1992;216:379-383. [Medline] [Order article via Infotrieve]
40.
Marklund S. Regulation by cytokines of
extracellular superoxide dismutase and other superoxide dismutase
isoenzymes in fibroblasts. J Biol Chem. 1992;267:6696-6701.
41.
Salvemini D, Misko T, Masferrer J, Seibert K, Currie M,
Needleman P. Nitric oxide activates cyclooygenase
enzymes. Proc Natl Acad Sci U S A. 1993;90:7240-7244.
42.
Tetsuka T, Daphna-Iken D, Srivastava S, Baier L,
DuMaine J, Morrison A. Cross-talk between
cyclooxygenase and nitric oxide pathways:
prostaglandin E2 negatively modulates induction
of nitric oxide synthase by interleukin 1. Proc Natl Acad
Sci U S A. 1994;91:12168-12172.
43. Kamijo R, Harada H, Matsuyama T, Bosland M, Gerecitano J, Shapiro D, Le J, Koh S, Kimura T, Green S, et al. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science. 1994;263:1610-1615.
44.
Xie Q, Kashiwabara Y, Nathan C. Role of
transcription factor NF-kB/Rel in induction of nitric oxide
synthase. J Biol Chem. 1994;269:4705-4708.
45.
Xie Q, Whisnant R, Nathan C. Promoter of the
mouse gene encoding calcium-independent nitric oxide synthase
confers inducibility by interferon-
and
lipopolysaccharide. J Exp Med. 1993;177:1779-1784.
46.
Lowenstein C, Alley E, Raval P, Snowman A, Snyder S,
Russell S, Murphy W. Macrophage nitric oxide synthase
gene: two upstream regions mediate induction by interferon-
and
lipopolysaccharide. Proc Natl Acad Sci
U S A. 1994;90:9730-9734.
47.
Siebenlist U, Franzoso G, Brown K. Structure,
regulation and function of NF-
B. Annu Rev Cell
Biol. 1994;10:405-455.
This article has been cited by other articles:
![]() |
X. Xu, J. Pang, H. Yin, M. Li, W. Hao, C. Chen, and J.-M. Cao Hexarelin suppresses cardiac fibroblast proliferation and collagen synthesis in rat Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2952 - H2958. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Libert, J. Bonnefont, E. Bourinet, E. Doucet, A. Alloui, M. Hamon, J. Nargeot, and A. Eschalier Acetaminophen: A Central Analgesic Drug That Involves a Spinal Tropisetron-Sensitive, Non-5-HT3 Receptor-Mediated Effect Mol. Pharmacol., September 1, 2004; 66(3): 728 - 734. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Farivar, L. H. Cohn, E. G. Soltesz, T. Mihaljevic, J. D. Rawn, and J. G. Byrne Transcriptional profiling and growth kinetics of endothelium reveals differences between cells derived from porcine aorta versus aortic valve Eur. J. Cardiothorac. Surg., October 1, 2003; 24(4): 527 - 534. [Abstract] [Full Text] [PDF] |
||||
![]() |
Safety Assessment of Salicylic Acid, Butyloctyl Salicylate, Calcium Salicylate, C12-15 Alkyl Salicylate, Capryloyl Salicylic Acid, Hexyldodecyl Salicylate, Isocetyl Salicylate, Isodecyl Salicylate, Magnesium Salicylate, MEA-Salicylate, Ethylhexyl Salicylate, Potassium Salicylate, Methyl Salicylate, Myristyl Salicylate, Sodium Salicylate, TEA-Salicylate, and Tridecyl Salicylate International Journal of Toxicology, June 1, 2003; 22(3_suppl): 1 - 108. [Abstract] [PDF] |
||||
![]() |
R. S. Farivar, F. Filsoufi, and D. H. Adams Mechanisms of Gal{alpha}1-3Gal{beta}1-4GlcNAc-R ({alpha}Gal) expression on porcine valve endothelial cells J. Thorac. Cardiovasc. Surg., February 1, 2003; 125(2): 306 - 314. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Tian, J. Liu, P. B. Bitterman, and R. J. Bache Mechanisms of cytokine induced NO-mediated cardiac fibroblast apoptosis Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1958 - H1967. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Giuliano, J. A. Mitchell, and T. D. Warner Sodium Salicylate Inhibits Prostaglandin Formation without Affecting the Induction of Cyclooxygenase-2 by Bacterial Lipopolysaccharide in Vivo J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 894 - 900. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Gustafsson and L. L. Brunton beta -Adrenergic Stimulation of Rat Cardiac Fibroblasts Enhances Induction of Nitric-Oxide Synthase by Interleukin-1beta via Message Stabilization Mol. Pharmacol., April 13, 2001; 58(6): 1470 - 1478. [Abstract] [Full Text] |
||||
![]() |
Z. Wang and P. Brecher Salicylate Inhibits Phosphorylation of the Nonreceptor Tyrosine Kinases, Proline-Rich Tyrosine Kinase 2 and c-Src Hypertension, January 1, 2001; 37(1): 148 - 153. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shimpo, U. Ikeda, Y. Maeda, K.-i. Ohya, Y. Murakami, and K. Shimada Effects of Aspirin-Like Drugs on Nitric Oxide Synthesis in Rat Vascular Smooth Muscle Cells Hypertension, May 1, 2000; 35(5): 1085 - 1091. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Wang, X. Yu, R. A. Cohen, and P. Brecher Distinct Effects of N-Acetylcysteine and Nitric Oxide on Angiotensin II-induced Epidermal Growth Factor Receptor Phosphorylation and Intracellular Ca2+ Levels J. Biol. Chem., April 14, 2000; 275(16): 12223 - 12230. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kitakaze, H. Asanuma, S. Takashima, T. Minamino, Y. Ueda, Y. Sakata, M. Asakura, S. Sanada, T. Kuzuya, and M. Hori Nifedipine-Induced Coronary Vasodilation in Ischemic Hearts Is Attributable to Bradykinin- and NO-Dependent Mechanisms in Dogs Circulation, January 25, 2000; 101(3): 311 - 317. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Wang and P. Brecher Salicylate Inhibition of Extracellular Signal-Regulated Kinases and Inducible Nitric Oxide Synthase Hypertension, December 1, 1999; 34(6): 1259 - 1264. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Jiang, M. Haverty, and P. Brecher N-Acetyl-L-Cysteine Enhances Interleukin-1{beta}-Induced Nitric Oxide Synthase Expression Hypertension, October 1, 1999; 34(4): 574 - 579. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Wang, X. Yu, and P. Brecher Nitric Oxide Inhibits Angiotensin II-induced Activation of the Calcium-sensitive Tyrosine Kinase Proline-rich Tyrosine Kinase 2 without Affecting Epidermal Growth Factor Receptor Transactivation J. Biol. Chem., August 20, 1999; 274(34): 24342 - 24348. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. Vandivier, A. Eidsath, S. M. Banks, H. L. Preas II, S. B. Leighton, P. J. Godin, A. F. Suffredini, and R. L. Danner Down-Regulation of Nitric Oxide Production by Ibuprofen in Human Volunteers J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1398 - 1403. [Abstract] [Full Text] |
||||
![]() |
K. Katsuyama, M. Shichiri, H. Kato, T. Imai, F. Marumo, and Y. Hirata Differential Inhibitory Actions by Glucocorticoid and Aspirin on Cytokine-Induced Nitric Oxide Production in Vascular Smooth Muscle Cells Endocrinology, May 1, 1999; 140(5): 2183 - 2190. [Abstract] [Full Text] |
||||
![]() |
D. Wang, X. Yu, and P. Brecher Nitric Oxide and N-Acetylcysteine Inhibit the Activation of Mitogen-activated Protein Kinases by Angiotensin II in Rat Cardiac Fibroblasts J. Biol. Chem., December 4, 1998; 273(49): 33027 - 33034. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Katsuyama, M. Shichiri, F. Marumo, and Y. Hirata NO Inhibits Cytokine-Induced iNOS Expression and NF-{kappa}B Activation by Interfering With Phosphorylation and Degradation of I{kappa}B-{alpha} Arterioscler Thromb Vasc Biol, November 1, 1998; 18(11): 1796 - 1802. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Harms, I. Ramirez, and H. Peña-Cortés Inhibition of Wound-Induced Accumulation of Allene Oxide Synthase Transcripts in Flax Leaves by Aspirin and Salicylic Acid Plant Physiology, November 1, 1998; 118(3): 1057 - 1065. [Abstract] [Full Text] |
||||
![]() |
R. K. Dubey, D. G. Gillespie, and E. K. Jackson Adenosine Inhibits Collagen and Protein Synthesis in Cardiac Fibroblasts : Role of A2B Receptors Hypertension, April 1, 1998; 31(4): 943 - 948. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. LaPointe and J. R. Sitkins Phospholipase A2 Metabolites Regulate Inducible Nitric Oxide Synthase in Myocytes Hypertension, January 1, 1998; 31(1): 218 - 224. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Pagano, J. K. Clark, M. E. Cifuentes-Pagano, S. M. Clark, G. M. Callis, and M. T. Quinn Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: Enhancement by angiotensin II PNAS, December 23, 1997; 94(26): 14483 - 14488. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Takizawa, M. Gu, A. V. Chobanian, and P. Brecher Effect of Nitric Oxide on DNA Replication Induced by Angiotensin II in Rat Cardiac Fibroblasts Hypertension, November 1, 1997; 30(5): 1035 - 1040. [Abstract] [Full Text] |
||||
![]() |
R. K. Dubey, D. G. Gillespie, Z. Mi, and E. K. Jackson Exogenous and Endogenous Adenosine Inhibits Fetal Calf Serum–Induced Growth of Rat Cardiac Fibroblasts : Role of A2B Receptors Circulation, October 21, 1997; 96(8): 2656 - 2666. [Abstract] [Full Text] |
||||
![]() |
J.-L. Balligand and P. J. Cannon Nitric Oxide Synthases and Cardiac Muscle : Autocrine and Paracrine Influences Arterioscler Thromb Vasc Biol, October 1, 1997; 17(10): 1846 - 1858. [Abstract] [Full Text] |
||||
![]() |
G. Kwon, J. R. Hill, J. A. Corbett, and M. L. McDaniel Effects of Aspirin on Nitric Oxide Formation and De Novo Protein Synthesis by RINm5F Cells and Rat Islets Mol. Pharmacol., September 1, 1997; 52(3): 398 - 405. [Abstract] [Full Text] |
||||
![]() |
R. S. Farivar and P. Brecher Salicylate Is a Transcriptional Inhibitor of the Inducible Nitric Oxide Synthase in Cultured Cardiac Fibroblasts J. Biol. Chem., December 6, 1996; 271(49): 31585 - 31592. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Kelly, J.-L. Balligand, and T. W. Smith Nitric Oxide and Cardiac Function Circ. Res., September 1, 1996; 79(3): 363 - 380. [Full Text] |
||||
![]() |
A. M. Silva and L. F. L. Reis Sodium Salicylate Induces the Expression of the Immunophilin FKBP51 and Biglycan Genes and Inhibits p34cdc2 mRNA Both in Vitro and in Vivo J. Biol. Chem., November 10, 2000; 275(46): 36388 - 36393. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |